An advocacy organization focused on seniors has reported notable enhancements in vaccine accessibility in New Brunswick, although it pointed out a persistent issue in a recent assessment. CanAge rated New Brunswick at a B-plus grade, placing it in a tie for third position alongside Newfoundland and Labrador and Yukon. In comparison, neighboring provinces Nova Scotia and Prince Edward Island achieved higher scores this year, receiving A-minus and A-plus ratings.
Laura Tamblyn-Watts, the CEO of CanAge, expressed optimism about the progress, noting that New Brunswick had previously ranked poorly but has made significant improvements, particularly in funding major vaccines that were previously not covered. She highlighted advancements in various vaccines, including a senior-specific influenza vaccine, as well as vaccines for pneumonia, RSV, and COVID. Additionally, the transition to digital vaccine records in the province has streamlined vaccination documentation processes, eliminating the need for paper-based records.
Acknowledging the significance of the high ranking for Atlantic Canada due to its aging population, Tamblyn-Watts emphasized a notable deficiency in New Brunswick’s vaccine coverage – the absence of the shingles vaccine. She underscored the severity of shingles, emphasizing its potential to cause blindness and its recurrent nature. Despite the substantial costs associated with the shingles vaccine, which typically range from $200 to $300 per shot, she highlighted the financial burden it poses, especially for individuals on fixed incomes.
Tamblyn-Watts stressed the broader societal benefits of widespread vaccination beyond individual health, citing reduced hospitalizations and alleviated strain on emergency rooms as compelling reasons to prioritize vaccination efforts.
